| 产品描述: | MJN110 是一种口服有效且选择性的单酰基甘油脂肪酶 (MAGL) 抑制剂,对 hMAGL 和 2-花生四烯酸甘油酯 (2-AG) 的 IC50 分别为 9.1 nM 和 2.1 nM。MJN110 可以产生阿片类活性分子保护作用,具有很强的抗痛觉过敏活性。 |
| 靶点: |
IC50: 9.1 nM (hMAGL) and 2.1 nM (2-AG) |
| 体外研究: |
MJN110 (0.01-1000 nM; 4 hours) has the primary serine hydrolase target, hMAGL, with an IC50 of ~1 nM and 10- and 100-fold selectivity windows over ABHD6 and LYPLA1/2, respectively. |
| 体内研究: |
MJN110 (i.p.; 0.0818 mg/kg; twice daily for 5.5 days) reverses chronic constriction injury (CCI)-induced mechanical allodynia and thermal hyperalgesia in a dose-dependent manner. The respective ED50 value (95% confidence limits) is 0.430 (0.233-0.793) mg/kg. |
| 参考文献: |
1. Wilkerson JL, et al. The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. J Pharmacol Exp Ther. 2016 Apr;357(1):145-56.
2. Niphakis MJ, et al. Evaluation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors. ACS Chem Neurosci. 2013 Sep 18;4(9):1322-32. |
| 溶解性: |
soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.163 ml |
10.815 ml |
21.63 ml |
| 5 mM |
0.433 ml |
2.163 ml |
4.326 ml |
| 10 mM |
0.216 ml |
1.081 ml |
2.163 ml |
| 50 mM |
0.043 ml |
0.216 ml |
0.433 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |